8-K: Natures Sunshine Reports Strong First Quarter 2025 Results, Announces Share Repurchase Program

Natures Sunshine Products, Inc. announced a 2% increase in net sales and a 20% increase in adjusted EBITDA for the first quarter of 2025, along with a new share repurchase program.

Summary

• Natures Sunshine Products reported its financial results for the first quarter ended March 31, 2025.
• Net sales increased by 2% to $113.2 million, compared to $111.0 million in the same quarter last year; in constant currency, net sales increased by 5%.
• GAAP net income attributable to common shareholders rose by 104% to $4.7 million, or $0.25 per diluted common share, compared to $2.3 million, or $0.12 per diluted common share, in the prior year.
• Adjusted EBITDA increased by 20% to $11.0 million, compared to $9.2 million in the same quarter last year.
• The company's board of directors authorized the repurchase of up to $25 million of the company's common shares, supplementing the $8.3 million remaining under the current authorization.
• Gross profit margin increased to 72.1% compared to 71.2% in the year-ago quarter, driven by price increases and effective savings initiatives.
• The company continues to expect full year 2025 net sales to range between $445 $470 million and adjusted EBITDA to range between $38 $44 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, including increased net income and adjusted EBITDA, and the announcement of a share repurchase program. The management's comments are optimistic, and the company's performance reflects the power of its global growth strategies.

Positives

• Net sales increased by 2% to $113.2 million compared to $111.0 million year-over-year.
• GAAP net income attributable to common shareholders increased by 104% to $4.7 million, or $0.25 per diluted common share.
• Adjusted EBITDA increased by 20% to $11.0 million.
• Gross profit margin improved to 72.1% from 71.2%.
• The company authorized a share repurchase program of up to $25 million.
• Net cash provided by operating activities was $2.6 million for the three months ended March 31, 2025, compared to $2.2 million in the prior year period.

Negatives

• Net sales in North America decreased by 4.1%.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties, including those related to trade restrictions, government regulations, direct selling laws, product registration, legal challenges, product liability claims, anti-bribery laws, and the ability to attract and retain independent consultants.
• Fluctuations in foreign exchange rates could negatively impact financial results.
• Supply chain disruptions, manufacturing interruptions, or the failure to accurately forecast customer demand could adversely affect the company's performance.
• Cybersecurity threats and data loss pose a risk to the company's operations.
• The company faces risks associated with its joint venture for operations in China.

Future Outlook

Natures Sunshine expects full year 2025 net sales to range between $445 $470 million and adjusted EBITDA to range between $38 $44 million.

Management Comments

• 2025 got off to a strong start, as first quarter revenue came in at $113 million, up 5% on a constant currency basis, and adjusted EBITDA came in at $11 million, up 20% versus prior year, said Terrence Moorehead, CEO of Natures Sunshine.
• Were particularly pleased with the exceptional growth were seeing in Asia and Europe where markets like Taiwan, Japan and Central Europe continue to deliver strong double-digit growth.
• Were also pleased to see early signs of stabilization in North America and continued improvements to gross margin.
• Despite the tremendous amount of uncertainty in the market, we remain confident in the underlying health of our business, and our performance reflects the power of our global growth strategies.
• In addition, our Board has authorized the repurchase of up to $25 million in common stock, supplementing the $8.3 million remaining under the current authorization, as we continue to make disciplined investments with the highest potential return for our shareholders.

Industry Context

Natures Sunshine's focus on high-quality herbal and nutritional supplements aligns with the growing consumer interest in natural health and wellness products. The company's global presence allows it to capitalize on growth opportunities in various markets, particularly in Asia and Europe.

Comparison to Industry Standards

• Direct comparison to industry standards is challenging without specific competitor data, but Natures Sunshine's gross margin of 72.1% suggests a strong position in managing production costs and pricing.
• Companies like Herbalife Nutrition and Nu Skin Enterprises are key competitors in the nutritional supplement and direct selling space.
• Herbalife reported a gross profit margin of around 76% in their latest results, while Nu Skin's was around 75%, indicating that Natures Sunshine is slightly below these benchmarks but still competitive.
• The share repurchase program is a common strategy among publicly traded companies to return value to shareholders, and the $25 million authorization is a significant commitment.

Stakeholder Impact

• Shareholders will benefit from the increased profitability and the share repurchase program.
• Independent consultants may see increased sales opportunities due to the company's growth in Asia and Europe.
• Customers will continue to have access to high-quality herbal and nutritional supplements.

Next Steps

• The company will hold a conference call to discuss the first quarter 2025 results.
• The company will continue to execute its share repurchase program.
• The company will focus on achieving its full year 2025 net sales and adjusted EBITDA targets.

Key Dates

Keywords

Financial Results, Share Repurchase, Adjusted EBITDA, Net Sales, Natures Sunshine, NATR